As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Capricor Therapeutics, Inc. The largest reported stake is Tang Capital Management, LLC's, at 7.1%. 11 filings are on record since July 29, 2025 (Schedule 13G/A, August 14, 2026).
Who owns Capricor Therapeutics, Inc.?
Sell to companies like Capricor Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Millennium Management LLC · Sole voting: 0 · Shared voting: 1,669,083 · Sole dispositive: 0 · Shared dispositive: 1,669,083 · SCHEDULE 13G/A, 2026-10-14
- · Holder: Millennium Management LLC · Percent: 5.1% · SCHEDULE 13G
- · Holder: Millennium Management LLC · Percent: 4.9% · SCHEDULE 13G
- · Reporting person: Tang Capital Management, LLC · Sole voting: 0 · Shared voting: 4,099,900 · Sole dispositive: 0 · Shared dispositive: 4,099,900 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: State Street Corporation · Sole voting: 0 · Shared voting: 3,285,634 · Sole dispositive: 0 · Shared dispositive: 3,397,241 · SCHEDULE 13G, 2026-08-07
Capricor Therapeutics, Inc. has 11 Schedule 13D or 13G filings on record since 2025-07-29. 4 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Tang Capital Management, LLC | 7.1% | 4,099,900 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Suvretta Capital Management, LLC | 6.6% | 3,417,891 | SCHEDULE 13G, 2026-02-26 | 2026-02-19 |
| State Street Corporation | 5.9% | 3,397,241 | SCHEDULE 13G, 2026-08-07 | 2026-06-30 |
| RA Capital Management, L.P. | 5.2% | 3,014,183 | SCHEDULE 13G, 2026-08-03 | 2026-07-27 |
| The Vanguard Group | 4.82% | 2,206,719 | SCHEDULE 13G/A, 2025-10-30 | 2025-09-30 |
| Millennium Management LLC | 2.9% | 1,669,083 | SCHEDULE 13G/A, 2026-10-14 | 2026-09-30 |
| Highbridge Capital Management, LLC | 2.3% | 1,200,000 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
Holding shares or following this stake? See who's behind Capricor Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Capricor Therapeutics, Inc. and the records around it.
Capricor Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- SUVRETTA CAPITAL MANAGEMENT, LLC also filed stake reports on 22 other companies: Veradermics, Inc (Aug 2026), Abeona Therapeutics Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Skye Bioscience, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026)
- Highbridge Capital Management, LLC also filed stake reports on 83 other companies: Aeon Acquisition I Corp. (Aug 2026), Alpex Acquisition Corp (Aug 2026), Aperture AC (Aug 2026)
Watch Capricor Therapeutics, Inc.
Get an email when Capricor Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Capricor Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Capricor Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Capricor Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Tang Capital Management, LLC | 0 | 4,099,900 | 0 | 4,099,900 | SCHEDULE 13G/A, 2026-08-14 |
| Kevin Tang | 0 | 4,099,900 | 0 | 4,099,900 | SCHEDULE 13G/A, 2026-08-14 |
| Tang Capital Partners, LP | 0 | 923,783 | 0 | 923,783 | SCHEDULE 13G/A, 2026-08-14 |
| Tang Capital Partners International, LP | 0 | 1,281,251 | 0 | 1,281,251 | SCHEDULE 13G/A, 2026-08-14 |
| Tang Capital Partners Iii, Inc | 0 | 877,133 | 0 | 877,133 | SCHEDULE 13G/A, 2026-08-14 |
| Tang Capital Partners Iv, Inc | 0 | 1,017,733 | 0 | 1,017,733 | SCHEDULE 13G/A, 2026-08-14 |
| State Street Corporation | 0 | 3,285,634 | 0 | 3,397,241 | SCHEDULE 13G, 2026-08-07 |
| RA Capital Management, L.P. | 0 | 3,014,183 | 0 | 3,014,183 | SCHEDULE 13G, 2026-08-03 |
| Peter Kolchinsky | 0 | 3,014,183 | 0 | 3,014,183 | SCHEDULE 13G, 2026-08-03 |
| Rajeev Shah | 0 | 3,014,183 | 0 | 3,014,183 | SCHEDULE 13G, 2026-08-03 |
| RA Capital Healthcare Fund, L.P. | 0 | 3,014,183 | 0 | 3,014,183 | SCHEDULE 13G, 2026-08-03 |
| Millennium Management LLC | 0 | 1,669,083 | 0 | 1,669,083 | SCHEDULE 13G/A, 2026-10-14 |
| Millennium Group Management LLC | 0 | 1,669,083 | 0 | 1,669,083 | SCHEDULE 13G/A, 2026-10-14 |
| Israel A. Englander | 0 | 1,669,083 | 0 | 1,669,083 | SCHEDULE 13G/A, 2026-10-14 |
The latest filing identifies Capricor Therapeutics, Inc. by CUSIP 14070B309 and gives its principal executive office as 10865 Road to the Cure, Suite 150, San Diego, CA 92121 (SCHEDULE 13G/A, 2026-10-14).
What the percentages are based on
Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.RA Capital Management, L.P., SCHEDULE 13G, 2026-08-03
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-29 | The Vanguard Group | 5.04% | SCHEDULE 13G |
| 2025-10-30 | The Vanguard Group | 4.82% | SCHEDULE 13G/A |
| 2026-01-26 | Tang Capital Management, LLC | 6.6% | SCHEDULE 13G |
| 2026-02-17 | Highbridge Capital Management, LLC | 2.3% | SCHEDULE 13G/A |
| 2026-02-26 | Suvretta Capital Management, LLC | 6.6% | SCHEDULE 13G |
| 2026-08-03 | RA Capital Management, L.P. | 5.2% | SCHEDULE 13G |
| 2026-08-07 | State Street Corporation | 5.9% | SCHEDULE 13G |
| 2026-08-14 | Tang Capital Management, LLC | 7.1% | SCHEDULE 13G/A |
| 2026-08-19 | Millennium Management LLC | 4.9% | SCHEDULE 13G |
| 2026-09-14 | Millennium Management LLC | 5.1% | SCHEDULE 13G |
| 2026-10-14 | Millennium Management LLC | 2.9% | SCHEDULE 13G/A |
Questions about who owns Capricor Therapeutics, Inc.
Who owns Capricor Therapeutics, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Capricor Therapeutics, Inc.: Tang Capital Management, LLC (7.1%, Schedule 13G/A, filed 2026-08-14), Suvretta Capital Management, LLC (6.6%, Schedule 13G, filed 2026-02-26), State Street Corporation (5.9%, Schedule 13G, filed 2026-08-07) and RA Capital Management, L.P. (5.2%, Schedule 13G, filed 2026-08-03).
Who are the largest shareholders of Capricor Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Capricor Therapeutics, Inc. on this page are Tang Capital Management, LLC (7.1%), Suvretta Capital Management, LLC (6.6%) and State Street Corporation (5.9%).
When did Tang Capital Management, LLC buy into Capricor Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Tang Capital Management, LLC on this page is the Schedule 13G, filed 2026-01-26, reporting 6.6%; its latest, Schedule 13G/A filed 2026-08-14, reports 7.1%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Capricor Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.